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1 These authors contributed equally to this article.PA-binding domain of LF (LFn) or PA-binding domain of EF (EFn) is the anthrax protective antigen
(PA) binding domain of anthrax lethal factor (LF) or edema factor (EF). Here we show the develop-
ment of a novel anthrax toxin inhibitor, fusion protein of N-terminal 27 amino acids deletion of LFn
(D27LFn) and EFn. In a cell model of intoxication, fusion protein of D27LFn and EFn (D27LFn–EFn)
was a 62-fold more potent toxin inhibitor than LFn or EFn, and this increased activity corresponded
to a 39-fold higher PA-binding afﬁnity by Biacore analysis. More importantly, D27LFn–EFn could
protect the highly susceptible Fischer 344 rats from anthrax lethal toxin challenge. This work sug-
gested that D27LFn–EFn has the potential as a candidate therapeutic agent against anthrax.
Structured summary:
MINT-7014735, MINT-7014747, MINT-7014761: PA63 (uniprotkb:P13423) and LF (uniprotkb:P15917)
bind (MI:0407) by surface plasmon resonance (MI:0107)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bacillus anthracis, the causative agent of anthrax infection, se-
cretes two toxins which are comprised of three proteins: protective
antigen (PA), a pore-forming protein; lethal factor (LF), a Zn-depen-
dent endopeptidase that cleaves some members of the MAPKK
family of intracellular signaling proteins; and edema factor (EF),
a calmodulin-activated adenylate cyclase that increases cAMP con-
centration of eukaryotic cells [1]. It is believed that anthrax toxins
play a role in all stages of anthrax infection. At the late stage of
infection, even antibiotics have been administered, the infection
can still be lethal because of the accumulation of the toxins. Logi-
cally, an effective therapeutic approach would include simulta-
neous killing of B. anthracis by antibiotics and inhibition of
anthrax toxin with toxin inhibitors.chemical Societies. Published by E
ctor; EF, edema factor; LFn,
f EF; D27LFn, N-terminal 27
ein of D27LFn and EFn
Applied Molecular Biology,
0 Dongdajie, Fengtai, Beijing
cw789661@yahoo.com (W.To exert its lethal effect, anthrax toxin must enter inside the
host cell. PA (83 kDa) binds to speciﬁc cellular receptors/tumor
endothelial marker 8 (TEM8) or capillary morphogenesis protein
2 (CMG2) [2,3] and is digested by a furin-like protease of the host
cell into two fragments, PA20 and PA63, the latter heptamerizes to
form a receptor-bound prepore and binds both LF and EF. The tox-
in–receptor complex is then internalized by receptor-mediated
endocytosis and trafﬁcked to a low-pH endosome where acidic
conditions induce conversion of the prepore to a pore, and EF
and LF are liberated into the cytosol by moving through the pore.
PA-binding domain of LF (LFn) or PA-binding domain of EF (EFn)
is the PA63 binding domain of LF or EF. They share 50% sequence
similarity with each other. LFn was sufﬁcient for binding PA63
and could act as a carrier for delivery of heterologous proteins
across membranes in the presence of PA [4].
Several studies on anthrax toxin inhibitors have been pub-
lished in recent years. These include dominant-negative mutants
of PA [5], toxin-neutralizing antibodies [6,7], soluble receptors
[8], and small molecular inhibitors of LF, EF [9,10]. Here we de-
scribed the construction of a novel anthrax toxin inhibitor, genet-
ically fused D27LFn (N-terminal 27 amino acids deletion of LFn)
and EFn, and presented in vitro and in vivo studies that indicate
this fusion protein has potential as a novel therapeutic agent
against anthrax.lsevier B.V. All rights reserved.
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2.1. Construction of plasmids
Plasmids and primers used in the study are listed in Table 1.
Primers LF5 and LFn3 were used to amplify the coding sequence
of LFn (aa 1–263 of LF) from B. anthracis; Primers D27LFn and
LFn3 were used to amplify the coding sequence of D27LFn (aa
28–263 of LF); Primers EF5 and EFn3 were used to amplify the cod-
ing sequence of EFn (aa 1–254 of EF). Puriﬁed PCR products of LFn,
D27LFn and EFn were cut with NdeI and XhoI and cloned into
pET21a (Novagen), respectively, resulting in plasmids pET21a-
LFn, pET21a-D27LFn and pET21a-EFn. A two-step procedure was
used to construct expression vectors of fusion protein of D27LFn
and EF (D27LFn–EF) and fusion protein of D27LFn and EF
(D27LFn–EF). First, primers D27LFn and LFn-Linker3 (containing
a (Gly4Ser)3 linker) were used to amplify the coding sequence of
D27LFn-Linker which then were cloned into pET21a using 50NdeI
and 30BamHI restriction sites, resulting in plasmid pET21a-
D27LFn-Linker. Then, coding sequence of EFn and EF were ampli-
ﬁed using primer pairs EF-Fusion5/EFn3 and EF-Fusion5/EF3,
respectively, and were cloned into pET21a-D27LFn-Linker using
50BamHI and 30XhoI restriction sites. The two recombinant plas-
mids were named as pET21a-D27LFn-EFn and pET21a-D27LFn-
EF. The same procedure was used to construct the expression
vector of fusion protein of LFn and EF (LFn–EF). First, primers
LFn5 and LFn-Linker3 were used to amplify the coding sequence
of LFn-Linker which then was cloned into pET21a, resulting in plas-
mid pET21a-LFn-Linker. Then, coding sequence of EF was ampliﬁed
with primer pairs EF-Fusion5/EF3, and was cloned into pET21a-
LFn-Linker. The ﬁnal plasmid was named as pET21a-LFn-EF.
2.2. Preparation of proteins
Escherichia coli strain BL21 (DE3) transformed by plasmids
pET21a-LFn, pET21a-EFn, pET21a-D27LFn, pET21a-D27LFn-EFn,
pET21a-D27LFn-EF, or pET21a-LFn-EF, respectively, was grown in
LB broth at 37 C until OD600 was between 0.6 and 0.7. Then, IPTG
(0.5 mmol/L) was added to the culture to induce the expression of
recombinant proteins at 28 C for 3 h. The bacteria pellet was har-
vested by centrifugation, resuspended in the 20 mmol/L Tris buffer
(pH 9.0), and lysed by sonication in ice bath. The insoluble debris in
the lysate was removed by centrifugation and the clear superna-
tant was collected for the puriﬁcation. The Ni-chelating columnTable 1
Plasmids and primers used in the study.
Plasmids or primers Phenotype or sequence
Plasmids
pET21a Expression vector containing 6His ta
pET21a-LFn Vector for expression of LFn (aa 1–263
pET21a-EFn Vector for expression of EFn (aa 1–254
pET21a-D27LFn Vector for expression of D27LFn (aa 2
pET21a-D27LFn-Linker Vector containing D27LFn and a (G4S)
pET21a-D27LFn-EFn Vector for expression of D27LFn–EFn,
pET21a-D27LFn-EF Vector for expression of D27LFn–EF, d
pET21a- LFn-Linker Vector containing LFn and a (G4S)3 Lin









LFn-Linker3 aagggatccagagcccccgccaccagagcc(GE Healthcare) was equilibrated with buffer (20 mmol/L Tris,
50 mmol/L imidazole and 0.5 mol/L NaCl, pH 9.0). The clariﬁed
sample was applied to the column and the target protein was
eluted with a linear gradient from 50 mmol/L to 500 mmol/L imid-
azole. The proteins were further puriﬁed using a Superdex75 gel
ﬁltration column (GE Healthcare) with buffer PBS. The concentra-
tion of the puriﬁed proteins was determined using a BCA kit
(PIERCE), and the purity of the proteins was examined by SDS–
PAGE with coomassie blue staining.
2.3. Biomolecular interaction analysis (Biacore)
PA63 was prepared by trypsinization of PA [11]. Brieﬂy, puriﬁed
recombinant PA was incubated with trypsin (0.2 lg/ml) for 30 min
at 25 C in 25 mM HEPES, 1 mM CaCl2, 0.5 M EDTA, pH 7.5. The
reaction was stopped by addition of PMSF to 1 mM. Superdex75
was employed to separate PA63 and PA20.
All binding-kinetics experiments were performed using a BIA-
core 3000 instrument (GE Healthcare). PA63 was covalently linked
to the CM5 chip. Concentrations of different recombinant proteins
ranged from 0 nmol/L to 200 nmol/L in HBS-EP buffer (pH 7.4). Se-
rial injections were made at 20 ll/min at 25 C. To calculate the
binding constants, the data obtained were analyzed by BIAevalua-
tion software version 4.0. Results were the average of two indepen-
dent experiments.
2.4. In vitro intoxication experiments
J774A.1 cells intoxication experiments were performed with a
modiﬁed protocol described before [11]. Brieﬂy, Murine macro-
phage-like J774A.1 cells were grown to conﬂuence in wells of a
96-well plate. Then aliquots of 100 ll of medium containing PA
(100 ng/ml), LF (100 ng/ml) and various concentrations of fusion
proteins were added to the cells. After a 3-h incubation at 37 C,
cell viability was assessed by MTT staining.
2.5. Anthrax lethal toxin challenge experiments in rats
Rats challenge experiments were approved by the Animal Care
and Use Committee of our Institute. Male Fischer 344 rats (3/
group) were injected intravenously 300 ll/rat of lethal toxin
(40 lg of PA plus 10 lg of LF in PBS), or lethal toxin plus
D27LFn-EFn (213 lg or 426 lg per rat). Rats were monitored con-
tinuously for symptoms of intoxication and death for 48 h.Resource
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Fig. 2. In vitro intoxication assay. LFn, EFn, D27LFn and D27LFn–EFn were tested
for their ability to protect cells from intoxication by incubating J774A.1 cells with
100 ng/ml PA and 100 ng/ml LF mixed with varying amounts of proteins respec-
tively. Cell viability was then assessed 3 h later by MTT assay. Data points represent
the mean cell viability% values for triplicate samples.
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Recombinant EF was prepared as described before [12]. To mea-
sure cAMP accumulation inside cells, CHO-K1 cells were seeded at
1  104 cells per well in a 96-well plate. One day later, cells were
incubated with various concentrations of recombinant proteins
and PA (1 lg/ml) for 2 h. After removal of the culture medium,
the levels of cAMP were determined by enzyme immunoassay fol-
lowing the manufacturer’s instruction (The direct cAMP assay kit,
nonacetylated version, GE Healthcare).
3. Results and discussion
3.1. Expression and puriﬁcation of recombinant proteins
All recombinant proteins were produced in the cytoplasm of re-
combinant E. coli strains. They were all fused with a 6His tag and
could be puriﬁed with a Ni-chelating column. After an additional
size-exclusion chromatography step, LFn, EF, D27LFn, D27LFn–
EFn, LFn–EF andD27LFn–EF were obtained in high purity as judged
by SDS–PAGE (Fig. 1).
3.2. Fusion protein D27LFn–EFn had higher toxin neutralization
activity than LFn, EFn or D27LFn due to higher PA63 afﬁnity
LFn or EFn is the PA-binding domain of LF or EF. To determine
whether LFn and EFn have the potential as anthrax toxin inhibitors,
they were tested for the capacity to inhibit lethal toxin (LF plus PA)
induced cytotoxicity in J774A.1 cells. A concentration of 323 nmol/
L LFn or EFn (molar ratio was around 300:1 to PA) was needed to
obtain complete protection of cells (Fig. 2). The low potency of
LFn and EFn suggested that they might have low binding afﬁnity
to PA63. We then used Biacore to compare the binding kinetics
of LFn or LF to PA63. The observed KA value of LFn was
6.26  107 M1, 6.6-fold lower, compared with that of LF (Table
2). Therefore, the low potency of LFn correlates with the low bind-
ing afﬁnity of LFn to PA63.
A maximum of three molecules of LF or EF can bind simulta-
neously per PA63 heptamer [13]. Deleting 27 or 36 residues of
LFn strongly inhibited acid-triggered translocation of LFn across
the plasma membrane of CHO-K1 cells without signiﬁcantly affect-
ing binding to PA63 [14]. We hypothesized D27LFn, a 27 residuesFig. 1. Analysis of puriﬁed LFn, EFn, D27LFn, D27LFn–EFn, LFn–EF and D27LFn–EF
by SDS–PAGE. Lane 1, protein markers; lane 2, LFn (31 kDa); lane 3, EFn
(31 kDa); lane 4, D27LFn (29 kDa); lane 5, D27LFn–EFn (60 kDa); lane 6,
LFn–EF (120 kDa); and lane 7, D27LFn–EF (119 kDa).deleting form of LFn, could be more potent than LFn if one D27LFn
could inﬂuence the translocation of two LF or EF by destroying
PA63 channel or other unknown way. As shown in Fig. 2, a concen-
tration of 81 nmol/L D27LFn (molar ratio was around 75:1 to PA)
was sufﬁcient to obtain complete protection of cells, which meant
D27LFn was about 4-fold more potent than LFn. In binding-kinetics
study, the KA value of D27LFn was 1.58  108 M1, 2.5-fold higher
than that of LFn (Table 2), which suggests the 27 amino acids dele-
tion might enhance the afﬁnity of LFn to PA63.
It was reported that cross-linked LFn was a more potent anthrax
toxin inhibitor than LFn monomer [15]. We hypothesized fusion
protein of D27LFn and EFn could be better than D27LFn monomer.
To test this hypothesis, D27LFn–EFn was constructed and tested. A
concentration of 5.2 nmol/L D27LFn–EFn (molar ratio was around
5:1 to PA) was sufﬁcient to obtain complete protection (Fig. 2),
which meant D27LFn–EFn was 62-fold more potent than LFn and
about 15-fold more potent than D27LFn. The KA value of
D27LFn–EFn was 2.42  109 M1, 39-fold higher compared with
that of LFn, and 15-fold higher compared with that of D27LFn. So
the higher toxin neutralization activity of D27LFn-EFn correlates
with its higher afﬁnity to PA63.
3.3. D27LFn–EFn protected the rats against anthrax lethal toxin
challenge
The anti-toxin efﬁcacy of D27LFn–EFn was further evaluated in
Fischer 344 rats. Control rats injected with 10 lg of LF plus 40 lg of
PA died in about 65 min, while the rats receiving toxin and 426 lg
D27LFn–EFn (molar ratio was 16:1 to PA) were fully protected and
showed no signs of intoxication symptoms. A 2-fold lower concen-
tration of D27LFn–EFn (213 lg, molar ratio was 8:1 to PA) was not
effective in protecting the rats, although it did extend their survival
signiﬁcantly, to an average of 200 min, compared with the rats
receiving the toxin alone (Table 3).
3.4. Translocation of D27LFn–EFn
The structure of D27LFn–EFn is different from that of LFn/EFn:
it has two PA63 binding domains and its N terminus is truncated.
To explore the effects of those difference on the translocation, we
constructed two fusion proteins, LFn–EF and D27LFn–EF, and mea-
sured translocation activities of the constructs. In a cellular cAMP
Table 2
Kinetic parameters for binding of LF, EFn, D27LFn and D27LFn–EFn to PA63.
Protein ka kd KA KD
M1S1 ± S.D. S1 ± S.D. M1a ± S.D. Ma ± S.D.
LF 4.48  105 ± 1.63  105 1.09  103 ± 1.41105 4.12  108 ± 1.55  108 2.62  109 ± 9.90  1010
LFn 6.80  105 ± 7.14  104 1.12  102 ± 3.37  103 6.26107 ± 1.24  107 1.63  108 ± 3.25  109
D27LFn 4.46  105 ± 1.15  105 3.18  103 ± 1.05  103 1.58  108 ± 8.56  107 7.56  109 ± 4.32  109
D27LFn–EFn 1.27  106 ± 2.33  105 5.37  104 ± 7.64  105 2.42  109±7.85  108 4.37  1010 ± 1.43  1010
a The equilibrium association/dissociation constant is calculated from kinetic measurements of the association and dissociation rate constants according to KA = ka/kd or
KD = kd/ka. Data represent the mean values for two independent experiments.
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cells treated with PA plus LFn–EF appeared no obvious difference
with cells treated with PA plus EF. But cytoplasm cAMP level in
cells treated with PA plus D27LFn–EF was lower than cells treated
with PA and EF. These results suggested N-terminal truncations of
27 residues did inﬂuence the translocation of D27LFn–EF while the
two PA63 binding domains did not. We thought lower efﬁciency of
translocation may be a merit of D27LFn–EFn as a therapeutic drug,
for it may reduce the potential interference of the protein to the
normal function of host cells.
By preventing intoxication in vivo with an inhibitor: PA molar
ratio around 16:1, D27LFn–EFn seems less effective than soluble
receptors (sCMG2) or toxin-neutralizing antibodies [6–8]. But
D27LFn–EFn may have several advantages over them. First,
D27LFn–EFn was over expressed in E. coli system which is the sim-
ple and cheap way to obtain large quantities of recombinant pro-
teins. Second, PA antibodies would be non-effective againstTable 3








LeTx onlyc 0/3 65 ± 3 min
PBSd 3/3 >48 he
D27LFn–EFn (8:1) 0/3 272 ± 45 min 0.000652
D27LFn–EFn (16:1) 3/3 >48 h
a Molar ratio refers to D27LFn–EFn: PA.
b For comparisons to the LeTx-only control group, by t-test.
c LeTx-only group (40 lg of PA plus 10 lg of LF per rat).
d Negative control group receiving PBS and no LeTx.
e Rats were monitored >48 h.
Fig. 3. Analysis of cellular cAMP. CHO-K1 cells were treated with EF alone, EF + PA,
LFn–EF + PA, or D27LFn–EF + PAm respectively. A ﬁxed PA concentration, 1 lg/ml
and a series of 2-fold dilution of EF, LFn–EF, and D27LFn–EF were used. A
competition ELISA was used to detect the cAMP level in cell cytoplasm. Higher
OD450 value represents lower cAMP level in cell cytoplasm. Data points represent
the mean OD450 values for triplicate samples.genetically modiﬁed strains of B. anthracis that express antigeni-
cally altered forms of PA, while the therapeutic function of
D27LFn–EFn will not be affected as any altered forms of PA that re-
tains function will, presumably, still bind to LF/EF. Third, sCMG2
may inﬂuence normal physiological functions of natural CMG2,
while D27LFn–EFn may be safe as it does not have catalytic do-
main of anthrax toxin. In conclusion, the data presented here illus-
trate that D27LFn–EFn has the potential to act as a novel anthrax
toxin inhibitor.
Acknowledgments
We thank Drs. Xiaowei Zhou and Long Xu at Beijing Institute of
Biotechnology for helping Biacore experiments. This work was sup-
ported by National Natural Science Foundation of China (30300016
and 30571745) and National High Technology Research and Devel-
opment Program of China (2006AA02A232).
References
[1] Collier, R.J. and Young, J.A. (2003) Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19,
45–70.
[2] Bradley, K.A., Mogridge, J., Mourez, M., Collier, R.J. and Young, J.A. (2001)
Identiﬁcation of the cellular receptor for anthrax toxin. Nature 414, 225–229.
[3] Scobie, H.M., Rainey, G.J., Bradley, K.A. and Young, J.A. (2003) Human capillary
morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl.
Acad. Sci. USA 100, 5170–5174.
[4] Arora, N. and Leppla, S.H. (1993) Residues 1–254 of anthrax toxin lethal factor
are sufﬁcient to cause cellular uptake of fused polypeptides. J. Biol. Chem. 268,
3334–3341.
[5] Sellman, B.R., Mourez, M. and Collier, R.J. (2001) Dominant-negative mutants
of anthrax toxin subunit: an approach to therapy of anthrax. Science 292, 695–
697.
[6] Albrecht, M.T., Li, H., Williamson, E.D., et al. (2007) Human monoclonal
antibodies against anthrax lethal factor and protective antigen act
independently to protect against Bacillus anthracis infection and enhance
endogenous immunity to anthrax. Infect. Immun. 75, 5425–5433.
[7] Wild, M.A., Xin, H., Maruyama, T., Nolan, M.J., Calveley, P.M., Malone, J.D.,
Wallace, M.R. and Bowdish, K.S. (2003) Human antibodies from immunized
donors are protective against anthrax toxin in vivo. Nat. Biotechnol. 21, 1305–
1306.
[8] Scobie, H.M., Thomas, D., Marlett, J.M., Destito, G., Wigelsworth, D.J., Collier,
R.J., Young, J.A. and Manchester, M. (2005) Soluble receptor decoy protects rats
against anthrax lethal toxin challenge. J. Infect. Dis. 192, 1047–1051.
[9] Shoop, W.L., Xiong, Y., Wiltsie, J., et al. (2005) Anthrax lethal factor inhibition.
Proc. Natl. Acad. Sci. USA 102, 7958–7963.
[10] Shen, Y., Zhukovskaya, N.L., Zimmer, M.I., et al. (2004) Selective inhibition of
anthrax edema factor by adefovir, a drug for chronichepatitis B virus infection.
Proc. Natl. Acad. Sci. USA 101, 3242–3247.
[11] Zhang, J., Xu, J., Li, G., Dong, D., Song, X., Guo, Q., Zhao, J., Fu, L. and Chen, W.
(2006) The 2b2–2b3 loop of anthrax protective antigen contains a dominant
neutralizing epitope. Biochem. Biophys. Res. Commun. 341, 1164–1171.
[12] Dong, D., Xu, J., Song, X., Fu, L. and Chen, W. (2005) Expression and analysis of
biological activity of the recombination anthrax edema factor. Acta Microbiol.
Sin. 45, 459–462.
[13] Cunningham, K., Lacy, D.B., Mogridge, J. and Collier, R.J. (2002) Mapping the
lethal factor and edema factor binding sites on oligomeric anthrax protective
antigen. Proc. Natl. Acad. Sci. USA 99, 7049–7053.
[14] Zhang, S., Finkelstein, A. and Collier, R.J. (2004) Evidence that translocation of
anthrax toxin’s lethal factor is initiated by entry of its N terminus into the
protective antigen channel. Proc. Natl. Acad. Sci. USA 101, 16756–16761.
[15] Juris, S.J., Melnyk, R.A., Bolcome, R.E., Chan, J. and Collier, R.J. (2007) Cross-
linked forms of the isolated N-terminal domain of the lethal factor are potent
inhibitors of anthrax toxin. Infect. Immun. 75, 5052–5058.
